The whole study design initialized with the determination of 752 miRNA levels in 59 samples (first stage of the study): (i) control (n = 16), (ii) ovarian cancer with no BRCA1/2 mutation (-/-) (n = 33) and (iii) ovarian cancer with BRCA1 or BRCA2 mutation (+/+) (n = 10). The gene discussed is BRCA2; the disease is ovarian carcinoma.